HRAS G12C
|
Urothelial Cancer
|
HRAS G12C
|
Urothelial Cancer
|
tipifarnib Sensitive: C3 – Early Trials
|
tipifarnib Sensitive: C3 – Early Trials
|
HRAS G12C
|
SCCHN
|
HRAS G12C
|
SCCHN
|
tipifarnib Sensitive: D – Preclinical
|
tipifarnib Sensitive: D – Preclinical
|